Loading...
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of five checkpoint inhibitors. In the second-line setting, in patients who have progressed on cisplatin-based chemotherapy, pembrolizumab, atezolizumab, durvalumab, nivolumab and avelumab are United Stat...
Na minha lista:
| Udgivet i: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6066800/ https://ncbi.nlm.nih.gov/pubmed/30083254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918788310 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|